Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Agenus Glioblastoma Vaccine Extends Survival in Phase 2

July 2, 2014 8:30 am | News | Comments

Agenus announced Phase 2 study results showing that patients with newly diagnosed glioblastoma multiforme who received Prophage autologous cancer vaccine, added to the standard of care treatment, lived nearly twice as long as expected. Read more...

TOPICS:

UMD, GBSI Partner to Advance Antibody Standards

July 1, 2014 2:22 pm | News | Comments

The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards. Read more...

TOPICS:

NIH Adds New Clinical Sites in Undiagnosed Diseases Network

July 1, 2014 1:57 pm | News | Comments

The National Institutes of Health has awarded grants to six medical centers around the country to select from the most difficult-to-solve medical cases and together develop effective approaches to diagnose them. Read more...        

TOPICS:
Advertisement

PTC Therapeutics Begins Phase 3 Trial of Drug for Severe Cystic Fibrosis

July 1, 2014 1:36 pm | News | Comments

PTC Therapeutics announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Read more...         

TOPICS:

Childhood Vaccines Again Deemed Generally Safe

July 1, 2014 1:29 pm | by Mike Stobbe, AP Medical Writer | News | Comments

The latest analysis of childhood vaccines confirms they're generally safe. The report should be reassuring to parents, the researchers say. For example, there still is no evidence the measles-mumps-rubella vaccine causes autism. Nor is there any proof vaccines cause childhood leukemia. Read more...

TOPICS:

Innovation Reins in Runaway Pharma Spending

July 1, 2014 1:21 pm | by Nancy Dreyfus, Contributing Science Writer | Articles | Comments

To combat the rising costs of bringing a new drug to market, pharmaceutical companies have taken a variety of innovative approaches, according to the U.K. Office of Health Economics, such as deciding earlier in the R&D process to discontinue drugs lacking strong market prospects and better controlling clinical costs. Read more...

TOPICS:

CTI BioPharma Wraps Up Recruitment in Pivotal Trial of Myelofibrosis Drug

July 1, 2014 11:30 am | News | Comments

CTI BioPharma Corp. announced that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, without exclusion for low platelet counts. Read more...

TOPICS:

Ipsen Applies for US, EU GEP-NET Drug Marketing Authorizations

July 1, 2014 11:22 am | News | Comments

Ipsen announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline Depot 120 mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Read more...

TOPICS:
Advertisement

GlycoVaxyn Kicks Off Trial of UTI Vaccine

July 1, 2014 11:17 am | News | Comments

GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, announced the initiation of a Phase 1 clinical trial of a candidate vaccine to prevent infections caused by Extra-intestinal Pathogenic Escherichia coli (ExPEC), such as urinary tract infections (UTIs). Read more...

TOPICS:

Amgen’s Leukemia Drug Gets FDA Breakthrough Designation

July 1, 2014 11:10 am | News | Comments

Amgen announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to investigational bispecific T cell engager antibody blinatumomab, for adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia, a rapidly progressing cancer of the blood and bone marrow. Read more...

TOPICS:

Actavis Closes $28B Forest Deal

July 1, 2014 11:05 am | News | Comments

Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company - Brenton Saunders - is now the CEO of Actavis, and former Actavis Chairman and CEO Paul Bisaro will become executive chairman. Read more...

TOPICS:

Nanoparticles Prevent Bone Cancer, Strengthen Bones

July 1, 2014 10:54 am | News | Comments

A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital and has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression. Read more...

TOPICS:

Takeda, Sanofi Launch Diabetes Collaboration in Japan

June 30, 2014 10:27 pm | News | Comments

Sanofi K.K. and Takeda Pharmaceutical Co. Ltd. announced that the two companies have entered into an agreement to build a collaborative system within Japan in the field of diabetes awareness and education. Read more...          

TOPICS:

A New Way to Combat Drug Resistance in Melanoma

June 30, 2014 2:45 pm | News | Comments

Researchers have developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. Read more...

TOPICS:

Actavis Facing Generic Zubsolv Patent Challenge

June 30, 2014 2:40 pm | News | Comments

Actavis confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval of a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence. As a result, Orexo AB and Orexo US Inc. filed suit against Actavis. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading